Last Updated on October 11, 2024 by The Health Master
Global pharma major Lupin Limited has received approval for its droxidopa capsules, 100 mg, 200 mg, and 300 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA Ltd.
The product will be manufactured at Lupin’s facility in Nagpur, India.
Droxidopa capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH).
These indications are caused by primary autonomic failure (Parkinson’s disease, multiple system atrophy, and pure autonomic failure), dopamine beta- hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Droxidopa capsules had estimated annual sales of US$352 million in the US, according to IQVIA MAT December 2020.
Also read:
Aurobindo Pharma gets USFDA nod for generic Droxidopa capsules
Zydus Cadila gets USFDA nod for low Blood Pressure drug
Dr Reddy’s Labs launches generic Fluphenazine HCL tablets
Shilpa Medicare gets Import Alert from USFDA
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
Go to main website, click here
Follow and connect with us on Facebook and Linkedin
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here
